Please login to the form below

Not currently logged in
Email:
Password:

wet AMD

This page shows the latest wet AMD news and features for those working in and with pharma, biotech and healthcare.

Bayer to challenge Avastin legal ruling

Bayer to challenge Avastin legal ruling

age-related macular degeneration (wet AMD) in place of two licensed but much more expensive treatments, Bayer’s Eylea and Novartis’ Lucentis. ... The NHS in England spends around £500m on licensed wet AMD treatments every year, with around £300m

Latest news

More from news
Approximately 18 fully matching, plus 46 partially matching documents found.

Latest Intelligence

  • Pharma deals during May 2014 Pharma deals during May 2014

    Top of the list was Ophthotech's commercialisation and co-development agreement with Novartis for Fovista, an anti-PDGF agent, in phase 3 for wet age-related macular degeneration (AMD). ... Coincidentally two weeks earlier, there was another deal for a

  • Deal Watch table for March 2014 Deal Watch table for March 2014

    22. Tracon Pharmaceuticals/ Santen Pharmaceutical Co. Licence. Tracon's anti‐endoglin antibodies, including TRC105 for wet AMD (p2).

  • Interview: Beate Wieseler, IQWIG Interview: Beate Wieseler, IQWIG

    effectiveness over Novartis' Lucentis (ranibizumab) in the treatment of wet age-related macular degeneration (AMD).

  • Revolution or evolution: is it the end of SMR and ASMR in France? Revolution or evolution: is it the end of SMR and ASMR in France?

    An example of this is Lucentis in wet age-related macular degeneration (AMD), where the expectation is that there should be pricing parity between Lucentis and Avastin, an oncology drug used

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics